Journal of Korean Medical Science

Korean Acad Medical Sciences (대한의학회)
권호 표지
DOI QR코드

DOI QR Code

Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy

  • Kim, Do Kyung (Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Koo, Kyo Chul (Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Lee, Kwang Suk (Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Hah, Yoon Soo (Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Rha, Koon Ho (Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Hong, Sung Joon (Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Chung, Byung Ha (Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine)
  • Received : 2018.01.23
  • Accepted : 2018.08.07
  • Published : 2018.11.05
⟨ Previous Next ⟩

Abstract

Background: Robot-assisted radical prostatectomy (RARP) is a feasible treatment option for high-risk prostate cancer (PCa). While patients may achieve undetectable prostate-specific antigen (PSA) levels after RARP, the risk of disease progression is relatively high. We investigated metastasis-free survival, cancer-specific survival (CSS), and overall survival (OS) outcomes and prognosticators in such patients. Methods: In a single-center cohort of 342 patients with high-risk PCa (clinical stage ${\geq}T3$, biopsy Gleason score ${\geq}8$, and/or PSA levels ${\geq}20ng/mL$) treated with RARP and pelvic lymph node dissection between August 2005 and June 2011, we identified 251 (73.4%) patients (median age, 66.5 years; interquartile range [IQR], 63.0-71.0 years) who achieved undetectable PSA levels (< 0.01 ng/mL) postoperatively. Survival outcomes were evaluated for the entire study sample and in groups stratified according to the time to biochemical recurrence dichotomized at 60 months. Results: During the median follow-up of 75.9 months (IQR, 59.4-85.8 months), metastasis occurred in 38 (15.1%) patients, most often to the bones, followed by the lymph nodes, lungs, and liver. The 5-year metastasis-free, cancer-specific, and OS rates were 87.1%, 94.8%, and 94.3%, respectively. Multivariate Cox-regression analysis revealed time to recurrence as an independent predictor of metastasis (P < 0.001). Time to metastasis was an independent predictor of OS (P = 0.003). Metastasis-free and CSS rates were significantly lower among patients with recurrence within 60 months of RARP (log-rank P < 0.001). Conclusion: RARP confers acceptable oncological outcomes for high-risk PCa. Close monitoring beyond 5 years is warranted for early detection of disease progression and for timely adjuvant therapy.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea

References

  1. Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990-2007. World J Urol 2008;26(3):211-8. https://doi.org/10.1007/s00345-008-0250-7
  2. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR; CaPSURE. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003;170(6 Pt 2):S21-5. https://doi.org/10.1097/01.ju.0000095025.03331.c6
  3. Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009;101(18):1280-3. https://doi.org/10.1093/jnci/djp262
  4. Chung BH. The role of radical prostatectomy in high-risk prostate cancer. Prostate Int 2013;1(3):95-101. https://doi.org/10.12954/PI.13018
  5. Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 2005;173(5):1557-61. https://doi.org/10.1097/01.ju.0000154610.81916.81
  6. Koo KC, Cho JS, Bang WJ, Lee SH, Cho SY, Kim SI, et al. Cancer-specific mortality among korean men with localized or locally advanced prostate cancer treated with radical prostatectomy versus radiotherapy: a multi-center study using propensity scoring and competing risk regression analyses. Cancer Res Treat 2018;50(1):129-37. https://doi.org/10.4143/crt.2017.004
  7. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17(5):1499-507. https://doi.org/10.1200/JCO.1999.17.5.1499
  8. Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, et al. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol 2012;61(3):584-92. https://doi.org/10.1016/j.eururo.2011.11.043
  9. Musch M, Pluemer J, Roggenbuck U, Klevecka V, Kroepfl D. Clinically high-risk prostate cancer patients comprise a relevant number of cancers with overall favorable tumor characteristics. World J Urol 2015;33(1):85-92. https://doi.org/10.1007/s00345-014-1274-9
  10. Walz J, Joniau S, Chun FK, Isbarn H, Jeldres C, Yossepowitch O, et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 2011;107(5):765-70. https://doi.org/10.1111/j.1464-410X.2010.09594.x
  11. Ploussard G, Masson-Lecomte A, Beauval JB, Ouzzane A, Bonniol R, Buge F, et al. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification. Urology 2011;78(3):607-13. https://doi.org/10.1016/j.urology.2011.05.021
  12. Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007;51(5):1175-84. https://doi.org/10.1016/j.eururo.2007.01.015
  13. Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, et al. Natural history of surgically treated high-risk prostate cancer. Urol Oncol 2015;33(4):163.e7-13. https://doi.org/10.1016/j.urolonc.2014.11.018
  14. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294(4):433-9. https://doi.org/10.1001/jama.294.4.433
  15. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, et al. Prostate cancer, version 1.2016. J Natl Compr Canc Netw 2016;14(1):19-30. https://doi.org/10.6004/jnccn.2016.0004
  16. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 2011;117(13):2883-91. https://doi.org/10.1002/cncr.25900
  17. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 2010;116(22):5226-34. https://doi.org/10.1002/cncr.25456
  18. Lee DH, Jung HB, Chung MS, Lee SH, Chung BH. The change of prostate cancer treatment in Korea: 5 year analysis of a single institution. Yonsei Med J 2013;54(1):87-91. https://doi.org/10.3349/ymj.2013.54.1.87
  19. Pompe RS, Karakiewicz PI, Tian Z, Mandel P, Steuber T, Schlomm T, et al. Oncologic and functional outcomes after radical prostatectomy for high or very high risk prostate cancer: European validation of the current NCCN(R) guideline. J Urol 2017;198(2):354-61. https://doi.org/10.1016/j.juro.2017.02.070
  20. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000;164(1):101-5. https://doi.org/10.1016/S0022-5347(05)67457-5
  21. Kang HW, Lee JY, Kwon JK, Jeh SU, Jung HD, Choi YD. Current status of radical prostatectomy for high-risk prostate cancer. Korean J Urol 2014;55(10):629-35. https://doi.org/10.4111/kju.2014.55.10.629
  22. Lee BH, Kibel AS, Ciezki JP, Klein EA, Reddy CA, Yu C, et al. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence. Eur Urol 2015;67(2):204-9. https://doi.org/10.1016/j.eururo.2014.09.017
  23. Jayadevappa R, Chhatre S, Whittington R, Bloom BS, Wein AJ, Malkowicz SB. Health-related quality of life and satisfaction with care among older men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy. BJU Int 2006;97(5):955-62. https://doi.org/10.1111/j.1464-410X.2006.06128.x
  24. Kaplan RN, Rafii S, Lyden D. Preparing the “soil”: the premetastatic niche. Cancer Res 2006;66(23):11089-93. https://doi.org/10.1158/0008-5472.CAN-06-2407
  25. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7. https://doi.org/10.1001/jama.281.17.1591
  26. Klein EA, Bianco FJ, Serio AM, Eastham JA, Kattan MW, Pontes JE, et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol 2008;179(6):2212-6. https://doi.org/10.1016/j.juro.2008.01.107

Cited by

  1. Investigation of Information Acquisition Channel for Prostate Cancer High-Risk Group vol.19, pp.3, 2018, https://doi.org/10.22465/kjuo.2021.19.3.174